COPD's biomarker problem and how the field is solving it

Chronic obstructive pulmonary disease was, for most of its therapeutic history, treated as a single condition with progressive airflow obstruction. The treatment ladder was inhaled bronchodilators (long-acting beta-agonists and long-acting muscarinic antagonists), then dual or triple combinations, then inhaled corticosteroids in selected patients, then systemic management of exacerbations. The phenotype-matching apparatus that asthma developed was largely absent in COPD.

The arrival of biologics in COPD has changed this. Several anti-inflammatory biologics that target type-2 inflammation have demonstrated efficacy specifically in patients with elevated blood eosinophil counts. The trials were designed around this biomarker and the approvals followed it. The result is that prescribing in COPD now includes a categorical question - what is this patient's eosinophil count, and does it cross the threshold for biologic eligibility - that did not exist five years ago.

The deeper biomarker work is harder. Eosinophil count is a useful but blunt instrument; the actual underlying inflammatory pathology in COPD is heterogeneous, with neutrophilic, mixed, and pauci-granulocytic patterns each implying different mechanism targets. The pipeline behind the first-wave biologics includes anti-IL-33, anti-TSLP, anti-IL-5R, and several other mechanisms; the trials behind those programs are increasingly designed to identify subgroups by biomarker rather than to demonstrate broad efficacy.

This matters operationally because the COPD prescriber community is broader than the asthma biologic community. Many COPD patients are managed in primary care; biologic prescribing has historically been concentrated in specialty centers. The infrastructure for biomarker-guided prescribing - systematic eosinophil counts, follow-up panels, referral pathways for biologic candidates - is being built where it did not previously exist.

From a patient-experience perspective, the framing shift is also significant. A patient told they have COPD has, until recently, been told they have a progressive condition managed with inhalers. A patient told they have eosinophilic COPD, eligible for a specific biologic mechanism, is in a different conversation - one where mechanism, prognosis, and therapeutic option are all more specific. The communication challenge for clinicians and the comprehension burden for patients are real, but the precision of care is materially better than it was.

What the field is still working out is the imaging and exhaled-breath biomarker layer that asthma has at least partially. The promise of an aerosol-collected biomarker panel that distinguishes COPD phenotypes at the point of care is closer than it has been but is not yet routine. When it arrives, the biomarker question in COPD will look more like the biomarker question in asthma - and the therapeutic landscape will look correspondingly more sophisticated.